Skip to content Skip to footer
Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2022 Based on Total Deal Value

Shots: Post M&A deals, companies often cannot sail through a few key aspects of the partnership, such as limited ownership, exorbitant recovery costs, and poor integration process, leading to deal terminations. The improperly executed expansion program also contributes significantly to the failed partnership To tackle such scenarios, companies are cautious enough to make backup plans beforehand…

Read more

Twenty Women Leaders In Healthcare Industry

Twenty Women Leaders In Healthcare Industry

Shots: Trailblazing, inspiring, and emancipating, women’s contribution to society is highly significant. By breaking the shackles of orthodox social customs, they made an indistinguishable place in society that we all should be proud of Every year on the 8th of March, the world celebrates International Women’s Day as a day of observance for women’s triumph in the social,…

Read more

Insights+ Key Biosimilars Events of July 2022

Insights+ Key Biosimilars Events of July 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of July, Polpharma Biologics reported EMA's acceptance of MAA…

Read more